225 related articles for article (PubMed ID: 33452660)
41. Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine.
AlAhmed O; Way A; Akoghlanian S; Barbar-Smiley F; Lemle S; MacDonald D; Frost E; Wise K; Lee L; Ardoin SP; Sivaraman V
Lupus; 2021 Feb; 30(2):269-279. PubMed ID: 33307983
[TBL] [Abstract][Full Text] [Related]
42. Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVİD-19 Patient: A Case Report and Literature Review.
Imanova Yaghji N; Kan EK; Akcan S; Colak R; Atmaca A
Postgrad Med; 2021 Jun; 133(5):548-551. PubMed ID: 33583332
[No Abstract] [Full Text] [Related]
43. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.
Choudhuri AH; Duggal S; Ahuja B; Biswas PS
Indian J Med Microbiol; 2021 Apr; 39(2):159-170. PubMed ID: 33781656
[TBL] [Abstract][Full Text] [Related]
45. No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine.
Friedman D; Lovig L; Halushka M; Clancy RM; Izmirly PM; Buyon JP
Clin Exp Rheumatol; 2017; 35(5):857-859. PubMed ID: 28598777
[TBL] [Abstract][Full Text] [Related]
46. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.
Gasmi A; Peana M; Noor S; Lysiuk R; Menzel A; Gasmi Benahmed A; Bjørklund G
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1333-1343. PubMed ID: 33515285
[TBL] [Abstract][Full Text] [Related]
47. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.
García-Albéniz X; Del Amo J; Polo R; Morales-Asencio JM; Hernán MA
Eur J Epidemiol; 2022 Aug; 37(8):789-796. PubMed ID: 35943669
[TBL] [Abstract][Full Text] [Related]
48. Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety.
Cornet A; Andersen J; Tani C; Mosca M
Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33875571
[TBL] [Abstract][Full Text] [Related]
49. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
[TBL] [Abstract][Full Text] [Related]
51. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
Stremmel C; Kellnar A; Massberg S; Kääb S
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):497-502. PubMed ID: 32700555
[TBL] [Abstract][Full Text] [Related]
52. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19).
Chen CP; Lin YC; Chen TC; Tseng TY; Wong HL; Kuo CY; Lin WP; Huang SR; Wang WY; Liao JH; Liao CS; Hung YP; Lin TH; Chang TY; Hsiao CF; Huang YW; Chung WS; Cheng CY; Cheng SH;
PLoS One; 2020; 15(12):e0242763. PubMed ID: 33264337
[TBL] [Abstract][Full Text] [Related]
53. Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.
Thémans P; Dauby N; Schrooyen L; Lebout F; Delforge M; Nasreddine R; Libois A; Payen MC; Konopnicki D; Wuillaume F; Lescrainier C; Verlinden V; Dogné JM; Hamdani J; Musuamba FT
Br J Clin Pharmacol; 2021 Feb; 87(2):674-682. PubMed ID: 32559820
[TBL] [Abstract][Full Text] [Related]
54. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Nicolò M; Ferro Desideri L; Bassetti M; Traverso CE
Int Ophthalmol; 2021 Feb; 41(2):719-725. PubMed ID: 32946004
[TBL] [Abstract][Full Text] [Related]
55. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
In 't Veld AE; Jansen MAA; Ciere LCA; Moerland M
J Immunol Res; 2021; 2021():6659410. PubMed ID: 33763494
[TBL] [Abstract][Full Text] [Related]
56. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
[TBL] [Abstract][Full Text] [Related]
57. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
Takamasu E; Yokogawa N; Shimada K; Sugii S
Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
[TBL] [Abstract][Full Text] [Related]
58. Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
Osmani Z; Schrama TJ; Zacouris-Verweij W; Andersen J; Frankel S; Bultink IEM; Cornet A; van Vollenhoven RF
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33795484
[TBL] [Abstract][Full Text] [Related]
59. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Sarayani A; Cicali B; Henriksen CH; Brown JD
Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
[TBL] [Abstract][Full Text] [Related]
60. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.
Geamănu Pancă A; Popa-Cherecheanu A; Marinescu B; Geamănu CD; Voinea LM
J Med Life; 2014 Sep; 7(3):322-6. PubMed ID: 25408748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
